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Colorectal cancer (CRC) represents the third most common malig-
nancy and the second leading cause of cancer-related deaths
worldwide. Although immunotherapy has taken center stage in
mainstream oncology, it has shown limited clinical efficacy in
CRC, generating an urgent need for discovery of new biomarkers
and potential therapeutic targets. Galectin-1 (Gal-1), an endoge-
nous glycan-binding protein, induces tolerogenic programs and
contributes to tumor cell evasion of immune responses. Here, we
investigated the relevance of Gal-1 in CRC and explored its mod-
ulatory activity within the CD8+ regulatory T cell (Treg) compart-
ment. Mice lacking Gal-1 (Lgals1−/−) developed a lower number of
tumors and showed a decreased frequency of a particular popula-
tion of CD8+CD122+PD-1+ Tregs in the azoxymethane-dextran so-
dium sulfate model of colitis-associated CRC. Moreover, silencing
of tumor-derived Gal-1 in the syngeneic CT26 CRC model resulted
in reduced number and attenuated immunosuppressive capacity of
CD8+CD122+PD-1+ Tregs, leading to slower tumor growth. More-
over, stromal Gal-1 also influenced the fitness of CD8+ Tregs, high-
lighting the contribution of both tumor and stromal-derived Gal-1
to this immunoregulatory effect. Finally, bioinformatic analysis of a
colorectal adenocarcinoma from The Cancer Genome Atlas dataset
revealed a particular signature characterized by high CD8+ Treg
score and elevated Gal-1 expression, which delineates poor progno-
sis in human CRC. Our findings identify CD8+CD122+PD-1+ Tregs as a
target of the immunoregulatory activity of Gal-1, suggesting a po-
tential immunotherapeutic strategy for the treatment of CRC.
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Colorectal cancer (CRC) is the third most commonly diag-nosed malignancy and the second leading cause of worldwide
cancer-related deaths (1). In developed countries, early detection
through screening has improved the 5-y survival of patients with
CRC, but ∼25% of patients still present stage 4 disease, and an
additional 25 to 50% present with early-stage disease but go on to
develop metastatic disease (2). In CRC, immune checkpoint block-
ade therapies, targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4)
and programmed cell death protein-1 (PD-1)/programmed death
ligand-1 (PD-L1) pathways received regulatory approval for the
treatment of heavily mutated tumors that are mismatch-repair–
deficient (dMMR) or have high levels of microsatellite instability
(MSI-H) (∼15%). In contrast, immune checkpoint blockade ther-
apies are ineffective in tumors that are MMR-proficient and are
microsatellite-stable or have low levels of microsatellite instability
(∼85%). In these tumors, low tumor mutational burden and the
lack of immune cell infiltration have been proposed as mechanisms
of immune resistance (3). Thus, there is an impending need to
investigate novel mechanisms of immune evasion in CRC, to
identify novel biomarkers of clinical response and to develop
novel immunotherapeutic strategies.
Several immune regulatory pathways, commonly used by the
immune system to maintain homeostasis and prevent exuberant
inflammation, are coopted by cancer cells to evade or re-edit
antitumor immune responses, thus fostering local and systemic
immunosuppressive microenvironments (4). A well-documented
mechanism of immune escape includes the recruitment, expan-
sion, and differentiation of immunosuppressive cell populations,
including regulatory T cells (Tregs), which have a detrimental
role in cancer by suppressing antitumor effector T cells, natural
killer (NK) cells, and antigen-presenting cells (5, 6). While
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CD4+CD25+Foxp3+ Tregs have been extensively studied, lim-
ited information is available on the fate and function of CD8+
Tregs (7). The intrinsic differences between CD4+ and CD8+
T cells regarding antigen-driven activation suggest that CD4+ and
CD8+ Tregs may have nonredundant, and probably complementary
immunomodulatory functions in the context of tumor-immune
escape (7, 8). Nevertheless, and even though CD8+ Tregs were
originally described in the early 1970s (9), scarce information is
available regarding their role in tumor-immune escape (7, 8).
Moreover, definition of CD8+ Tregs remains a major drawback
given the paucity of specific markers and functional, transcrip-
tional, or epigenetic programs that could distinguish these cells
from conventional cytotoxic and memory CD8+ T cells (10, 11).
Recent studies brought CD8+ Tregs back into the spotlight
through the identification of distinct populations expressing a
different set of cell surface markers and displaying potent immu-
nosuppressive profiles (7, 8). Among them, a particular population
of antigen-elicited CD8+ Tregs expressing CD25, Foxp3, and
CTLA-4 has been detected in prostate, breast, and CRC (12).
Moreover, a group of inducible CD8+CD28− Tregs that promote
CD4+ T cell anergy has been identified in cancer patients (13–15).
Additionally, CD8+CD122+ Tregs have been described in mice in
different cancer models (16–20). This regulatory population, char-
acterized by high interleukin (IL)-10 production, blunts IL-17 and
interferon (IFN)-γ secretion from activated CD4+ T cells (8, 16)
and displays cytotoxic activity against effector T cells through Fas
ligand (Fas L)-dependent mechanisms (16, 17, 21). Accordingly,
administration of anti-CD122 monoclonal antibody (mAb) signifi-
cantly reduced tumor growth and induced long-term survival in
experimental models of CRC and melanoma (22). Further studies
revealed that CD8+CD122+ Tregs included subsets of regulatory
and memory T cells and suggested the use of PD-1 to discriminate
between these subpopulations. Whereas CD8+CD122+PD-1+ cells
function as Tregs, CD8+CD122+PD-1− cells exhibit features of
memory T cells (11). Interestingly, a CD8+CXCR3+ Treg pop-
ulation secreting high amounts of IL-10, but lacking CD122 ex-
pression, has been described in humans as an equivalent of murine
CD8+CD122+PD-1+ T cells (23).
Programmed remodeling of cell surface glycans controls tumor
progression by influencing different hallmarks of cancer cells,
including cell adhesion, invasion, angiogenesis, and immune es-
cape (24). Galectins, a family of endogenous glycan-binding proteins,
serve as “glyco-checkpoints” that reprogram the tumor microenvi-
ronment (TME) and recalibrate tumor-driven circuits through in-
tracellular and extracellular mechanisms (25). Galectin-1 (Gal-
1), a proto-type member of this family specifically recognizes
N-acetyllactosamine [LacNAc; Galβ (1-4)-GlcNAc] structures on
glycosylated receptors present on the surface of different cells
(26). Targeting Gal-1/glycan interactions suppresses tumor pro-
gression by thwarting tumor-immune escape (27–29), attenuating
aberrant angiogenesis (30–32), preventing metastasis (33), and
circumventing resistance to different anticancer therapies, including
immunotherapy (34, 35). Mechanistically, Gal-1 limits antitumor
immunity by promoting differentiation of tolerogenic dendritic cells
(DCs) (36), inducing apoptosis of effector T cells (27, 29), and fa-
voring expansion of CD4+Foxp3+ Tregs (28, 33). In this regard,
Gal-1 has emerged as a critical regulator of CD4+ Treg biology by
recalibrating the fate and function of these cells (28, 33, 37, 38).
Particularly in CRC, higher Gal-1 expression correlates with tumor
growth, survival, and progression (39–41). Moreover, recent find-
ings demonstrated that branched N-glycans, which commonly serve
as galectin ligands, may be coopted by CRC cells to evade antitu-
mor immunity through inhibition of IFN-γ production (42). How-
ever, the relevance of Gal-1 in CRC-driven immunosuppression has
not yet been explored.
Here we show that Gal-1 controls tumor growth in CRC by shaping
antitumor immunity through modulation of CD8+CD122+PD-1+
Tregs. Using the syngeneic CT26 CRC model and the colitis-
associated CRC model chemically induced by azoxymethane
(AOM) and dextran sodium sulfate (DSS), we demonstrate that
both tumor- and stromal-derived Gal-1 influence tumor growth
by controlling the frequency and suppressive activity of CD8+ Tregs.
Accordingly, bioinformatic analysis of colorectal adenocarcinoma
(COAD) patient datasets (The Cancer Genome Atlas, TCGA)
revealed a “poor prognosis signature” characterized by high Gal-1
expression and an elevated CD8+ Treg score, defined by phenotypic
and functional markers of these regulatory cells. Thus, targeting Gal-
1/glycan interactions may represent a potential immunotherapeutic
modality for treating CRC patients by recalibrating the CD8+ Treg
compartment.
Results
Mice Lacking Gal-1 Develop Fewer Tumors and Display Lower Frequency
of CD8+ Tregs in a Colitis-Associated CRC Model. To investigate the
immunoregulatory role of Gal-1 in CRC, we first used the AOM-
DSS colitis-associated CRC (CACRC) model, which recapitulates
the initiation and progression phases of human CACRC (43).
Both WT and Gal-1–deficient (Lgals1−/−) mice were subjected to
inflammation-driven colon carcinogenesis by treatment with AOM-
DSS (Fig. 1A). We found a substantial reduction in the number of
tumors developed in the distal colon of Lgals1−/− compared to WT
mice (**P < 0.01) (Fig. 1B). Given the involvement of Gal-1 in
regulatory immune programs, particularly CD4+ Tregs, in dif-
ferent pathologic settings (33, 37, 44), we analyzed the frequency
of different Treg cell populations in tumor-draining lymph nodes
(DLNs) and spleen of AOM-DSS–treated animals (Fig. 1 C and
D). While we found no substantial differences in the proportions
of CD4+CD25+Foxp3+, CD8+CD25+Foxp3+, or CD8+CD28−
Tregs between Gal-1–deficient and WT genotypes (Fig. 1C), the
percentage of PD-1+ cells on CD8+CD122+ Treg cells was sub-
stantially lower in tumor-bearing Lgals1−/− vs. WTmice, both in DLN
and spleen (Fig. 1D andE). Of note, modulation of NKT cells, which
also express CD122, was ruled out based on the concomitant analysis
of the NKT cell marker CD49b (SI Appendix, Fig. S1). Moreover,
study of activated and memory CD4+ and CD8+ T cell populations
revealed no differences in the frequency of these cells between WT
and Lgals1−/− animals (SI Appendix, Fig. S2). Thus, endogenous Gal-
1 favors CACRC tumorigenesis through selective modulation of
CD8+CD122+PD-1+ Tregs.
Gal-1 Increases the Frequency and Accentuates the Immunosuppressive
Capacity of CD8+ Tregs. To evaluate whether Gal-1 has an intrinsic
ability to control the CD8+ Treg compartment in a nonpathological
setting, we studied the frequency and function of CD8+ Tregs in
healthy WT and Lgals1−/− mice. Analysis of the frequency of
different Treg cell populations showed only a significant reduction in
the percentage of CD8+CD122+PD-1+ Tregs in axillary and ingui-
nal lymph nodes of Lgals1−/− compared to WT mice (Fig. 2 A–C),
consistent with the findings in the AOM-DSS CACRCmodel. These
results were validated both in the C57BL/6 and the BALB/c strains,
suggesting that modulation of this Treg population is strain-
independent and intrinsically associated with Gal-1 deficiency.
Notably, differences in CD8+ Treg frequency were not verified
in the spleen neither in BALB/c nor in C57BL/6 mice (Fig. 2 A–C).
Next, we evaluated the impact of endogenous Gal-1 on the
immunosuppressive capacity of CD8+CD122+PD-1+ Tregs us-
ing an in vitro lymphocyte proliferation assay. Mouse splenocytes
were fluorescently labeled and cocultured with increasing ratios
of sorted CD8+CD122+PD-1+ Tregs obtained fromWT or Lgals1−/−
C57BL/6 mice and analyzed by flow cytometry (Fig. 2 D–F). Notably,
CD8+CD122+PD-1+ Tregs from Lgals1−/− mice showed a signifi-
cantly lower suppressive capacity on both CD4+ and CD8+ effector
T cells as compared to WT CD8+ Tregs (Fig. 2 E and F). Similar
results were obtained using Lgals1−/− and WT splenocytes from
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BALB/c mice (SI Appendix, Fig. S3). Thus, although no significant
changes were observed in the proportion of CD8+CD122+PD-1+
Tregs in the spleen, substantial differences were found in their
immunosuppressive capacity.
Given the central role of IL-10 as a mediator of the immunosup-
pressive capacity of CD8+CD122+PD1+Tregs, we analyzed IL-10
secretion in supernatants from coculture experiments. Remarkably,
CD8+CD122+PD1+ Tregs obtained from Lgals1−/− mice secreted
lower amounts of IL-10 compared to CD8+CD122+PD1+ WT
Tregs (Fig. 2G). A marked decline in IFN-γ–producing T cells
was observed in cocultures of splenocytes with CD8+CD122+PD1+
Tregs from both WT and Lgals1−/− mice, compared to splenocytes
cultured in the absence of Tregs. However, the percentage of IFN-





Fig. 1. Endogenous Gal-1 promotes tumorigenesis in the AOM-DSS CACRC model and fosters an immunosuppressive tumor microenvironment via induction
of CD8+ Tregs. (A) Scheme of the AOM-DSS CRC model. (B) Number of tumors in the distal colon of Lgals1−/− compared to WT mice. (C) Analysis of
CD4+CD25+Foxp3+, CD8+CD25+Foxp3+, and CD8+CD28− T cells in tumor-DLN of Lgals1−/− versus WT mice. (D) Analysis of PD-1 expression in CD8+CD122+ T cells
in DLN and spleen of Lgals1−/− and WT mice. (E and F) Flow cytometry dot plot analysis showing gates for the selected immune populations. Data presented
are mean ± SEM from three independent experiments. n = 5 to 6 mice per group. Unpaired Student’s t test, *P < 0.05, **P < 0.01.
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exposed to Lgals1−/− CD8+CD122+PD1+ Tregs compared to
their WT counterpart (Fig. 2H). Thus, Gal-1 deficiency lowers the
frequency of CD8+CD122+PD-1+ Tregs and attenuates their
immunosuppressive capacity.
Tumor-Derived Gal-1 Fosters Immunosuppression in a Syngeneic CRC
Model through Induction of CD8+ Tregs. Since Gal-1 deletion controls
the frequency and suppressive activity of CD8+ Tregs and reduces







Fig. 2. Gal-1 augments the frequency and immunosuppressive capacity of CD8+CD122+PD-1+ Tregs. (A–C) Spleen and axillary and inguinal lymph nodes from WT or
Lgals1−/− C57BL/6 (Left) or BALB/c mice (Right) were processed and CD8+CD122+PD1+ (A), CD8+CD25+Foxp3+ (B), and CD8+CD28− (C) T cells were analyzed. (D) Schematic
representation of immunosuppression assays. CD8+CD122+PD-1+ Tregswere isolated from the spleens ofWT or Lgals1−/− C57BL/6mice andwere further coculturedwith total
labeled splenocytes at different ratios (1:1, 1:2, 1:4). (E and F) Proliferation and division rates of CD4+ and CD8+ responders T cells. (G) Determination of IL-10 in supernatants
of coculture assays at 96 h. (H) Frequency of IFN-γ+ T cells in splenocytes cocultured with CD8+CD122+PD1+ Tregs fromWT or Lgals1−/−mice detected by flow cytometry. Data
presented are the mean ± SEM from three independent experiments. n = 5 to 6 mice per group. ANOVA, Bonferroni multiple comparison test, *P < 0.05 and ***P < 0.001.
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role of tumor-derived Gal-1 in modulating the CD8+ Treg com-
partment using the syngeneic CT26 CRC model. Gal-1–deficient
and control CT26 cell lines were generated by stable transfection
with a Gal-1–specific small-hairpin RNA (shRNA) (CT26 Gal-1
knockdown, KD) or a scramble unspecific sequence (CT26 Scr).
Gal-1 KD resulted in ∼50% reduction of protein expression, as
determined by Western blot (Fig. 3A). Gal-1 KD, Scr, and WT
CT26 cells were subcutaneously injected into WT mice. Tumor
growth was significantly reduced in mice inoculated with Gal-1
KD cells compared to mice receiving WT or Scr cells (P < 0.05)
(Fig. 3B). Moreover, mice injected with Gal-1 KD cells showed a
significant reduction in the percentage of PD-1+ cells within the
CD8+CD122+ T cell population in tumor-infiltrating lymphocytes,
spleen, and DLN, as compared to mice receiving WT or Scr CT26
cells (Fig. 3C). In contrast, no significant differences were detected
in the frequencies of CD8+CD28−, CD8+CD25+Foxp3+, or
CD4+CD25+Foxp3+ Tregs obtained from animals inoculated with
Gal-1 KD or WT CT26 cells (SI Appendix, Fig. S4). Finally, WT
mice inoculated with Gal-1 KD cells showed higher percentages of
CD4+IFN-γ+ and CD8+IFN-γ+ T cells (Fig. 3D). Of note, Gal-1
silencing did not affect intrinsic proliferation or survival of CT26
cells (SI Appendix, Fig. S5), as previously described in other tumor
cells, including melanoma (29), lung cancer (30), Kaposi’s sarcoma
(31), and breast adenocarcinoma cells (33). These results highlight
the immune inhibitory activity of tumor-derived Gal-1 in CRC by
favoring expansion of CD8+CD122+PD-1+ Tregs.
To evaluate the role of tumor-derived Gal-1 on T cell fitness,
we isolated splenocytes from mice inoculated with Gal-1 KD,
Scr, or WT CT26 cells and analyzed their proliferative response
(Fig. 3 E–G). Interestingly, CD4+ T cells obtained from mice bearing
Gal-1 KD tumors showed enhanced proliferative response compared
to those isolated from mice bearing WT or Scr tumors (Fig. 3F).
Moreover, a significant increase in proliferation and division rates was
also observed in CD8+ T cells from Gal-1 KD tumor-bearing mice
(Fig. 3G).
To study the role of tumor-derived Gal-1 in the immunosup-
pressive capacity of CD8+CD122+PD-1+ Tregs in the CT26 CRC
model, we performed ex vivo immunosuppressive assays using
CD8+CD122+PD-1+ Tregs obtained from the spleens of mice in-
oculated with Gal-1 KD or WT CT26 cells cocultured with sple-
nocytes obtained from healthy WT mice (Fig. 3H). Remarkably,
CD8+CD122+PD-1+ Tregs obtained from mice bearing Gal-1 KD
CT26 tumors showed impaired T cell inhibitory activity, evidenced
by a significant increase in the division rate of CD8+ T cells (Fig. 3 I
and J), as compared to CD8+CD122+PD-1+ Tregs isolated from
mice bearing WT tumors. This effect was also reflected by a
significant drop in IL-10 secretion in supernatants of splenocytes
cocultured with CD8+CD122+PD-1+ Tregs isolated from mice
bearing Gal-1 KD tumors (Fig. 3K). Thus, tumor-derived Gal-1
increases the frequency of CD8+CD122+PD-1+ Tregs and ac-
centuates their immunosuppressive capacity in the syngeneic
CRC model.
Stromal-Derived Gal-1 Impacts the Immunosuppressive Capacity of
CD8+ Tregs In Vivo. Since Gal-1 is produced not only by tumor
cells but also by stromal cells, including fibroblasts, endothelial
cells, and immune cells (26, 28, 41), we next sought to evaluate
the impact of stromal-derived Gal-1 by analyzing the growth of Gal-
1 KD or WT CT26 tumor cells in Lgals1−/− or WT mice (Fig. 4A).
Notably, the slowest tumor growth rate was observed in Lgals1−/−
animals inoculated with CT26 KD cells (Fig. 4B), highlighting the
contribution of both tumor and stromal-derived Gal-1 to this effect.
When we analyzed the impact of tumor-derived Gal-1 in mod-
ulating CD8+ Tregs, we verified a reduction in the proportion of
CD8+CD122+PD-1+ T cells in the spleens, DLN, and tumors of
animals inoculated with CT26 Gal-1 KD cells, compared to mice
receiving CT26 WT cells (Fig. 4C), as previously observed in
Fig. 3C. Moreover, when comparing WT and Lgals1−/− mice
inoculated with CT26 WT cells, Gal-1–deficient mice showed a
lower proportion of CD8+CD122+PD-1+ T cells in the spleen
(Fig. 4C), highlighting the impact of endogenous stromal-derived
Gal-1 in the modulation of this CD8+ Treg population. Remark-
ably, CD8+ T cells obtained from the spleen of mice bearing Gal-1
KD CT26 tumors showed increased proliferative capacity, as
reflected by higher proliferation and division index, irrespective
of the host genotype. These results underscore the relevance of
tumor-derived Gal-1 in distant T cell-mediated immunoregula-
tion (Fig. 4 D and E). Notably, stromal Gal-1 did not show any
role in proliferation and division rates of CD4+ T cells obtained
from mice inoculated with either CT26 Gal-1 KD cells or WT
tumors (Fig. 4F). Taken together, these results suggest that both
tumor- and stromal-derived Gal-1 affect the rate and prolifera-
tive capacity of CD8+ T cells and influence tumor growth.
Prognosis of Human CRC Is Dictated by Gal-1 Expression and a CD8+
Treg Score. Given the role of Gal-1 in modulating the prolifera-
tion and immunosuppressive capacity of CD8+ Tregs in experi-
mental CRC models, we next examined whether high Gal-1
expression could correlate with heightened infiltration of CD8+
Tregs in a COAD patients TCGA dataset. Moreover, we sought
to investigate whether these parameters could be associated with
poor prognosis and survival. For this, we analyzed Gal-1 gene
(LGALS1) expression in these tumors and defined a CD8+ Treg
score as a gene signature involving key markers of human CD8+
Tregs (11). This allowed categorization of human tumors
according to the StepMiner one-step algorithm (SI Appendix,
Fig. S6A). High LGALS1 expression was associated with poor
prognosis in human COAD, evidenced by lower overall survival
and disease-specific survival (Fig. 5 A and B). Moreover, we found a
significant increase of the CD8+ Treg score in COAD samples
displaying higher LGALS1 expression (P < 0.001) (Fig. 5C). Next, we
evaluated LGALS1 expression during the course of CRC (Fig. 5D).
Interestingly, early-stage primary invasive adenocarcinomas showed
significantly lower LGALS1 expression than tumor stages II/III (P <
0.02) (Fig. 5D). In addition, we found higher LGALS1 expression on
the consensus molecular subtype (CMS)-4 (Fig. 5E) and on the
poorly immunogenic immune cancer subtype C6 (Fig. 5F), charac-
terized by a proangiogenic phenotype, high stromal infiltration, and
TGF-β activation (45, 46). Conversely, we found no significant as-
sociation between LGALS1 expression and MSI status or hyper-
methylation in human COAD samples (SI Appendix, Fig. S6 B and
C). However, there was a slight increase in LGALS1 expression in
MSI tumors compared to microsatellite stable tumors (SI Appendix,
Fig. S6D). Thus, a dynamic signature characterized by high LGALS1
expression and elevated CD8+ Treg score delineates poor prognosis
in human CRC.
Discussion
Although immunotherapy has achieved long-term durable re-
sponses in several malignancies, including melanoma, lung ade-
nocarcinoma, head and neck squamous cell carcinoma (HNSCC),
and metastatic renal cancer, in CRC this treatment modality is
restricted to patients with dMMR or MSI-H tumors (3). This
limitation urges the investigation of additional immune escape
mechanisms and the development of novel immunotherapeutic
approaches.
Aberrant glycosylation has emerged as a critical hallmark of
cellular oncogenesis and tumor progression, since altered glycan
structures play relevant roles in cancer signaling, migration, immu-
nomodulation, and metastasis (24, 47). These tumor-associated car-
bohydrates involve not only the under- or overexpression of naturally
occurring glycans, but also the neo-expression of glycan structures
Cagnoni et al. PNAS | 5 of 11
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Fig. 3. Tumor-derived Gal-1 increases the frequency of CD8+CD122+PD-1+ Tregs and accentuates their immunosuppressive capacity in the syngeneic CRC
model. (A) Gal-1 expression detected by Western blot in CT26 WT cells stably transfected with shRNA (CT26 Scr) or with Gal-1–specific shRNA (CT26 Gal-1 KD).
(B) Tumor growth kinetics in BALB/c mice subcutaneously inoculated with WT, Scr or Gal-1 KD CT26 cells. (C) Analysis of PD-1+ cells within the CD8+CD122+
T cell population isolated from the spleen, DLN, and tumors from mice inoculated with CT26 WT, Scr, or Gal-1 KD cells. (D) Flow cytometry analysis of
intracytoplasmic IFN-γ in CD8+- and CD4+-activated T cells. (E) Schematic representation of proliferation assays performed with CFSE-labeled splenocytes.
(F and G) Analysis of CD4+ and CD8+T cell proliferation and division index. (H) Schematic representation of suppression assays involving CD8+CD122+PD-1+ Tregs
and CD4+ and CD8+ T cells. (I and J) Proliferation and division index of CD4+ and CD8+ responder T cells. (K) Determination of IL-10 by ELISA in coculture
supernatants at 96 h. Data presented are mean ± SEM from a representative experiment. n = 5 mice per group. One- or two-way ANOVA, Bonferroni multiple
comparison test (A–G), or unpaired Student’s t test (H–I), *P < 0.05; **P < 0.01; ***P < 0.001.
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(24, 48). In CRC, changes in the tumor N-glycome may include
increased sialylation, decreased overall fucosylation, increased β(1−6)
branching of N-linked glycans and higher abundance of poly-LacNAc
chains, while O-glycans are altered by reduced expression of core 3
and core 4 structures and higher levels of (sialyl) T-antigen (core 1)





Fig. 4. Tumor- and stromal-derived Gal-1 contributes to the immunosuppressive microenvironment in CRC. (A) Experimental design. (B) Kinetics of tumor growth
in WT or Lgals1−/− BALB/c mice subcutaneously inoculated with WT or Gal-1 KD CT26 cells. (C) Analysis of PD-1 expression in the spleen, DLN, and tumor-infiltrating
CD8+CD122+ T cells detected by flow cytometry. (D) Schematic representation of the proliferation assays of CFSE-labeled splenocytes purified from WT or Lgals1−/−
mice bearing CT26 WT or Gal-1 KD tumors. (E and F) Flow cytometry analysis of CD4+ and CD8+ proliferation and division index. Data presented are mean ± SEM
from three independent experiments. n = 5 to 6 mice per group. ANOVA, Bonferroni multiple comparison test, *P < 0.05; **P < 0.01; and ***P < 0.001.
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functional characterization of glycans (51) uphold the potential
role of altered glycosylation as a promising therapeutic strategy
in cancer (52, 53). In this scenario, galectins have emerged as
regulatory glyco-checkpoints that control antitumor immunity by
inducing T cell exhaustion, limiting T cell survival and enhancing
expansion of CD4+ Tregs (38). These extracellular activities are
mostly mediated by recognition of permissive glycan structures
on the surface of immune cells. Interestingly, previous studies pro-
posed the assembly of a “galectin-glycan lattice” a dynamic spatial
array that may control galectin binding, cross-linking, and signaling.
These multivalent structures can regulate tumor progression by
shaping antitumor immunity, modulating tumor cell invasion and
promoting aberrant angiogenesis (25, 38, 54).
In this work, using the colitis-associated CRC model chemi-
cally induced by AOM-DSS and the syngeneic CT26 CRC model,
we identified a role of Gal-1 in CRC progression and immune es-
cape by modulating the frequency and immunosuppressive capacity
of CD8+CD122+PD-1+ Tregs. Through glycosylation-dependent
mechanisms, Gal-1 can reprogram the immune landscape of dif-
ferent tumor types, including melanoma (29, 55), lung adenocarci-
noma (27, 30), pancreatic adenocarcinoma (28), glioblastoma (56),
breast adenocarcinoma (33), and HNSCC (34) by dismantling the
effector function of CD4+ and CD8+ T cells, inducing tolerogenic
DCs, and favoring the expansion of CD4+CD25+Foxp3+ Tregs
(57). Similarly, other members of the galectin family—including
Gal-3, Gal-8, and Gal-9—play key roles in the control of CD4+
Tregs (58–60). However, the relevance of Gal-1 in modulating
the fate and function of CD8+ Tregs has not yet been explored.
Moreover, although Gal-1 is highly up-regulated in the circula-
tion and TME in early- and late-stage CRC patients (40, 41, 61),
the contribution of this lectin to CRC progression and underlying
immunosuppression is uncertain. We found that both tumor- and
stromal-derived Gal-1 accelerate tumor growth and promote im-
mune escape in two different experimental CRC models. More-
over, bioinformatic analysis revealed a strong association between
LGALS1 expression, CD8+ Treg score, and poor prognosis in a
COAD database, as reflected by lower overall survival and disease-
specific survival of human CRC patients. In this regard, recent find-
ings showed that branched N-glycans, which serve as Gal-1–specific
ligands, are coopted by CRC tumors to evade immune recognition
through inhibition of IFN-γ (42). Further studies are warranted to
elucidate whether a Gal-1–N-glycan lattice plays a central role in this
immune inhibitory circuitry.
To explore the molecular mechanism underlying the protu-
moral activity of Gal-1 in CRC, we studied the immunoregula-
tory function of this lectin in AOM-DSS colitis-associated CRC.
The molecular, immunological and mutational landscape of this
model recapitulates that associated with the CMS4 of CRC,
which, interestingly, exhibited the highest Gal-1 expression among
the four CMS analyzed in TCGA-COAD samples (Fig. 5). CMS4
represents poorly immunogenic tumors associated with bad prognosis
and characterized by high stromal infiltration, TGF-β activation, and
angiogenesis (45). Accordingly, high Gal-1 expression also correlated
with the poorly immunogenic immune cancer subtype C6, which is
portrayed by increased TGF-β signaling, negative prognosis, and
tumor-promoting immune infiltrate (46).
Notably, Lgals1−/− mice developed significantly fewer tumors
than WT mice in the AOM-DSS CRC model, indicating a critical
role for Gal-1 in CACRC progression. Since Gal-1 modulates the fate
and function of CD4+ Tregs in different physiologic and pathologic
settings, including pregnancy (62), autoimmune inflammation (44, 63),
and breast cancer metastasis (33), we speculated that this lectin could
impact the Treg cell compartment in CRC. Whereas Gal-1 targeting
did not induce any change in the proportion of CD4+ Tregs in the
tumor, DLN, and spleen of CRC-bearing mice and no alterations
were detected in inducible CD8+CD25+Foxp3+ or CD8+CD28−
Tregs, we found a selective modulation of CD8+CD122+PD-1+
Tregs in Lgals1−/− compared to WT mice.
To further analyze whether induction of CD8+CD122+PD-1+
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Fig. 5. In silico analysis of LGALS1 mRNA expression according to clinical, prognostic, and tumor-immune features of primary invasive human colorectal
adenocarcinomas (TCGA-COAD dataset). (A) Kaplan–Meier plot depicting overall survival of two colorectal tumor categories based on LGALS1 expression. (B)
Kaplan–Meier plot depicting disease-specific survival of two colorectal tumor categories based on LGALS1 expression. (C) CD8+ Treg score in low and high
LGALS1 expression tumor categories. (D–F) LGALS1 expression across colon adenocarcinoma samples categorized according to tumor stages I to IV (D), four
consensus molecular subtypes described by Guinney et al. (45) (E), and six immune phenotypes described by Thorsson et al. (46) (F). ANOVA, Bonferroni
multiple comparison test, *P < 0.05, **P < 0.01, ***P < 0.001.
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Gal-1 deficiency in the proportion of CD4+ and CD8+ Treg cell
populations in healthy animals. Notably, analysis of lymph nodes
of healthy Lgals1−/− mice showed a statistically significant re-
duction of CD8+CD122+PD-1+ T cells compared to WT mice,
highlighting the relevance of endogenous Gal-1 in shaping the
CD8+ Treg compartment even in the absence of pathologic
stimuli. Accordingly, CD8+CD122+PD-1+ Tregs obtained from
Lgals1−/− mice showed lower immunosuppressive capacity com-
pared to CD8+CD122+PD-1+ Tregs obtained from WT mice.
These results suggest that, in addition to other immunoregulatory
effects, Gal-1 can also reprogram the function of CD8+CD122+PD-
1+ Tregs. Notably, an elevated CD8+ Treg score was associated with
high LGALS1 expression, independently of the MSI status in a
TCGA-COAD database (Fig. 5), highlighting the connection be-
tween Gal-1 and CD8 Tregs and their correlation with poor prog-
nosis in CRC patients.
To discern the effect of stromal- and tumor-derived Gal-1 in
CRC biology and immunosuppressive potential, we explored the
role of this lectin in the syngeneic CT26 CRC model. Silencing of
tumoral Gal-1 suppressed tumor growth and reduced expansion
of CD8+CD122+PD-1+ Tregs. In this regard, Gao et al. (64) re-
cently reported CD8+ T cell-dependent inhibition of CRC metas-
tasis using PD-1 blocking agents by reducing Treg cell differentiation
and increasing IFN-γ production. In addition, Gal-1 silencing in-
creased the proliferative capacity of CD4+ and CD8+ splenic T cells,
thus confirming the role of tumor-derived Gal-1 in CRC-driven
immune escape. Furthermore, splenocytes cocultured with
CD8+CD122+PD-1+ Tregs obtained frommice bearing CT26 Gal-1
KD tumors secreted lower amounts of IL-10, as previously ob-
served in other tumor types (27, 30), thus substantiating the
immunosuppressive capacity of this lectin. Thus, Gal-1 secreted
by CRC contributes to immune escape through distinct mecha-
nisms, including selective expansion of the CD8+CD122+PD-1+
Tregs, enhancement of their immunosuppressive capacity via IL-
10, and inhibition of CD4+ and CD8+ T cell proliferation. Since
Gal-1 interacts with the T cell receptor (TCR) complex and CD45
and influences downstream signaling pathways on effector T cells
(65, 66), further studies should examine whether tumor Gal-1 may
differentially control TCR signaling and CD45 phosphatase activity
in CD8+ regulatory versus effector T cells. In this context, Gal-3 has
been shown to bind to immune checkpoint molecules, including
CTLA-4 and lymphocyte antigen-3 (LAG-3) on CD8+ T cells, thus
regulating their signaling threshold, activation and differentiation
(67, 68). In this regard, the precise mechanisms implicated in Gal-
1–driven induction of CD8+ Tregs and the control of their func-
tionality should be explored in detail, including a full characterization
of the glycosylation signature of these cells as well as the transcrip-
tional and epigenetic programs underlying these immunoregulatory
effects.
Finally, in addition to the contribution of tumoral Gal-1, our
findings also demonstrate the importance of stromal-derived Gal-1
by comparing injection of CT26WT and Gal-1 KD cells into WT or
Lgals1−/− mice. While tumoral Gal-1 showed a more pronounced
effect in regulating the proportion of CD8+ Tregs, both tumor- and
stromal-derived Gal-1 influenced the proliferation of CD8+ T cells
and the immunosuppressive capacity of CD8+CD122+PD-1+
Tregs. Lower Gal-1 expression, whether of stromal or tumor
origin, resulted in reduced tumor growth. Accordingly, Lgals1−/−
mice bearing Gal-1–silenced CT26 tumors showed the lowest tumor
growth rate among the different experimental conditions explored.
In the past years, Gal-1 has emerged as a multifunctional medi-
ator of cancer-driven immunosuppression, a reliable biomarker of
tumor prognosis, and a potential therapeutic target in different
cancer types (35). In this study we identified a role for Gal-1 in CRC
by shaping antitumor immunity through modulation of the fre-
quency and immunosuppressive function of CD8+CD122+PD-1+
Tregs. Moreover, bioinformatic analysis of TCGA-COAD datasets
revealed strong association between Gal-1 expression, CD8+ Treg
score and the prognosis of CRC patients. Thus, therapeutic tar-
geting of Gal-1 might contribute to overcome CRC-driven immu-
nosuppression and improve the clinical outcome of CRC patients.
Further exploration of combinatorial strategies involving Gal-1
blockade together with immunotherapy, chemotherapy, or anti-
angiogenic therapy might help increase the clinical effectiveness of
these treatments. In this regard, several Gal-1 inhibitors have al-
ready been developed, including small-molecule glycan inhibitors
(52, 69, 70), antagonistic peptides (32, 71), and specific neutralizing
mAb (31, 72).
Materials and Methods
Cell Lines and Cell Culture. The mouse colon carcinoma CT26 cell line was
purchased from the American Type Culture Collection (ATCC CRL-2638) and
maintained in RPMI 1640 (Sigma Aldrich) supplemented with 10% fetal
bovine serum (FBS, Biochrom AG) and 1% penicillin-streptomycin (PenStrep,
Gibco). Gal-1–specific shRNA was designed as previously described (31),
cloned into the pSIREN-RetroQ vector, and delivered using lipofectamine
(Invitrogen). After infection, cells were subjected to puromycin selection
(1 μg/mL) and further cultured in the presence of 0.1 μg/mL of this antibiotic.
Annexin V Binding Assay. CT26 cells (1 × 106 cells/mL) were incubated in RPMI
medium supplemented with 10% FBS and antibiotics. Apoptotic cells were
identified by staining with APC-conjugated annexin V (BD Biosciences) and
propidium iodide (PI). Cell death was determined as percent of annexin
V+PI+ cells.
Tumor Cell Proliferation Assay. CT26 cells (50,000 cells/mL) were cultured in a
24-well plate in RPMI medium supplemented with 10% FBS and antibiotics.
Cells were sequentially harvested with Triple Enzyme express (Gibco),
washed, centrifuged, and resuspended. Live cells were counted for 7 d using a
Countess automated cell counter (Thermo Fisher).
Mouse Strains. Mice were bred at the animal facility of the Instituto de
Biología y Medicina Experimental (IBYME) according to NIH guidelines. Gal-
1–deficient (Lgals1−/−) C57BL/6 mice were kindly provided by Francoise Poi-
rier, Jacques Monod Institute, Paris, France. BALB/c WT mice were obtained
from the Animal House of the School of Exact and Natural Sciences, Uni-
versity of Buenos Aires (Argentina). Lgals1−/− BALB/c mice were previously
generated by crossing C57BL/6 Lgals1−/− mice into BALB/c background for N9
generations. Purity of the BALB/c Lgals1−/− strain was confirmed by analyz-
ing a panel of specific microsatellites as short tandem repeats or simple
sequence-length polymorphism at Instituto Nacional de Tecnología Agro-
pecuaria, Buenos Aires, Argentina. All experimental procedures were
reviewed and approved by the Institutional Animal Care and Use Committee
of IBYME.
Cell Isolation and Flow Cytometry. After killing, tumors, spleen, and lymph
nodes were extracted and transferred to cold RPMI 1640 culture medium
(Gibco). Next, organs were homogenized in RPMI 1640 culture medium
supplemented with 10% FBS and antibiotics (2 U/mL penicillin, 2 μg/mL
streptomycin, and 5 ng/mL amphotericin B). Cells were then harvested by
centrifugation at 1,500 rpm for 5 min. To enrich tumor-infiltrating lym-
phocytes, a Percoll (Sigma-Aldrich) density gradient was performed. Cells
were stained with the corresponding mAbs against CD3, CD4, CD8, CD25,
CD28, CD44, CD62L, CD122, Foxp3, and PD-1 (BD Biosciences). Isotype-
matched irrelevant mAbs were used as negative controls. Intracytoplasmic
IFN-γ and Foxp3 staining was performed using fixation and permeabilization
buffers according to manufacturer’s instructions (eBioscience). Acquisition of
cell events was performed on a FACSCanto II flow cytometer (BD Biosciences)
and data were analyzed using FlowJo software.
Syngeneic CT26 CRC Model. WT, Gal-1 KD, or scramble CT26 cells were in-
jected into 6- to 8-wk-old BALB/c mice (5 × 105 cells in 100 μL PBS, subcu-
taneously, right flank). Tumor volume was calculated as follows: length ×
(width)2 × 0.5 (73). After 3 wk, or when primary tumors reached an average
volume of 1,000 mm3, animals were killed, tumors were surgically removed
and weighted.
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CACRC Model. Eight- to 10-wk-old C57BL/6 mice received an intraperitoneal
injection (10 mg/kg body weight) of AOM (Sigma- Aldrich) followed by 5 d
of DSS treatment (2.5%) and 14 d of recovery, as described previously (74).
This initial 19-d cycle was repeated three times. Body weight, presence of
rectal bleeding, and stool consistency were assessed three times per week,
recorded, and averaged to generate a clinical score (75). After the fourth
DSS cycle, mice were killed, colons were extracted, and the number of in-
testinal tumors was assessed.
Immunoblotting. Immunoblotting was performed essentially as described
previously (33). In brief, equal amounts of protein were resolved by SDS/
PAGE and blotted onto nitrocellulose membranes (GE Healthcare). After
blocking, membranes were incubated with rabbit antiactin mAb (I-19; Santa
Cruz Biotechnology) and rabbit anti–Gal-1 polyclonal IgG, obtained as pre-
viously described (31). Membranes were then incubated with horseradish
peroxidase (HRP)-labeled anti-rabbit secondary antibody (Bio-Rad) and de-
veloped using ECL Prime Western Blotting Detection Reagent (Amersham
Biosciences). Protein bands were analyzed with ImageJ software.
Cell Sorting of CD8+ Tregs. After killing, spleens were removed and cells were
isolated after by mechanical disaggregation and filtered, generating unicellular
suspensions. Erythrocytes were lysed by incubation in ACK lysis buffer (NH4Cl
0.15 M, KHCO3 10 mM, Na2EDTA 0.1 mM, pH 7.2 to 7.4) for 3 min. After cen-
trifugation, CD8+ T cells were purified using Negative Selection DynaBeads
Untouched Mouse CD8 cells kit (Invitrogen, Thermo Fisher Scientific) following
the manufacturer’s instructions. CD8+ T cells were resuspended in PBS buffer
supplemented with 1 mM EDTA, 25 mM Hepes pH 7.0, and 1% FBS, at a con-
centration of 100 × 106 cells/mL. Cells were incubated during 30 min on ice with
anti–CD8-APC (BD Biosciences), anti–CD3-PE-Cy5 (BD Biosciences), anti–CD122-
FITC (eBiosciences), and anti–PD-1-PE (BioLegend) labeled mAb. After 30 min,
cells were washed, centrifuged, and resuspended in the same buffer at a con-
centration of 10 to 25 × 106 cells/mL. Finally, CD8+CD122+PD-1+ T cells were
sorted on a FACS Aria II (BD) flow cytometer.
Lymphocyte Proliferation Assay. After killing, spleen, and lymph nodes were
extracted and immediately transferred to cold RPMI medium 1640 (Gibco).
Tissueswere homogenized, filtered, and cellswere collected by centrifugation at
1,500 rpm for 8min. Splenocyteswere resuspended in PBS and labeledwith 1 μM
carboxyfluorescein N-succinimidyl ester (CFSE) for 7 min at 37 °C. Reaction was
stopped and cells were collected by centrifugation, washed, and resuspended in
RPMI medium 1640 supplemented with 10% FBS. Cells were transferred to
U-bottom P-96 culture plates. To stimulate lymphocyte proliferation, plates
were previously coated with 100 μL of 1 μg/mL anti-CD3 mAb (BioXCell, 2 h at
37 °C). Cells were incubated at 37 °C and 5% CO2 during 96 h. Then, cells were
collected, washed, and stained in PBS pH = 7.4 supplemented with 0.5% BSA
with anti–CD4-PE-Cy5 (BD Biosciences) and anti–CD8-PE (30 min at 4 °C) anti-
bodies (eBiosciences). Proliferation of responder cells was determined by CFSE
dilution and analyzed by flow cytometry. Accordingly, division rate was calcu-
lated as the number of total divisions per number of total original cells and the
proliferation rate was determined as the number of total divisions per number
of divided original cells.
Suppression Assay. CD3+CD8+CD122+PD-1+ T cells were sorted as previously
described from the spleens of WT or Lgals1−/− mice. Responder T cells were
obtained from spleen homogenates from WT mice, resuspended in PBS, la-
beled with 1 μM CFSE during 7 min at 37 °C, and cocultured with WT or
Lgals1−/− CD8+ Tregs in 10% FBS RPMI (Treg:responder T cells ratio 1:1, 1:2,
and 1:4). Controls included cultures performed in the absence of Tregs. After
96 h at 37 °C, cells were harvested, washed, and stained in PBS buffer pH =
7.4 supplemented with 0.5% BSA with anti–CD4-PE-Cy-5 and (BD Biosci-
ences) anti–CD8-PE antibodies (eBiosciences) for 30 min at 4 °C. Proliferation
of responder T cells was analyzed in a FACS Aria II (BD) flow cytometer.
ELISA. Mouse IL-10 was determined in supernatants using a specific ELISA kit
(BD Biosciences) according to the manufacturer’s instructions and relativized
to total protein.
Bioinformatics Analysis. In silico analysis of LGALS1 mRNA in association to a
defined CD8+ Treg score and clinical data were performed in tumor and im-
mune cell populations using data obtained from a TCGA-COAD cohort. Clinical
data and preprocessed RNA-sequencing normalized mRNA data of 259 primary
invasive colon adenocarcinomas were obtained from the University of Cal-
ifornia, Santa Cruz (UCSC) Xena browser (https://xenabrowser.net/). Univariate
and bivariate expression analysis among cases were performed with the R
software. To further explore the prognostic value of the gene-expression sig-
nature driven by LGALS1 (high or low), we evaluated the colon adenocarci-
nomas dataset. Briefly, cancer patients with gene-expression signature and
follow-up data were divided into two subgroups for the survival analyses of
LGALS1 expression (low Gal-1 or high Gal-1). Discretization of the LGALS1 gene
expression data into low- or high-expression levels was performed according
the StepMiner one-step algorithm of their respective profiles (http://genedesk.
ucsd.edu/home/public/StepMiner/). These two groups were then compared
based on the overall survival and disease-specific survival (Kaplan–Meier curves
and log-rank test) using the Survival and Survminer R packages. Cancer-
associated immune subtypes (C1 to C6) were directly retrieved from the UCSC
Xena resource and CD8+ Treg score was computed as a weighted sum of the
CD8+ Treg signature of the following algebraic expression: CD8A + CXCR3 +
IL2RA + FOXP3 − CD28 − CD4. Curated molecular subtypes and associated
categories (consensus molecular subtypes, molecular subtypes, hypermethylation
categories, and MSI status) were retrieved using the TCGA biolinks R/Bio-
conductor package (76).
Statistical Analysis. Statistical analysis was performed using GraphPad Prism
5.0 Software (GraphPad). Two-way ANOVA and Bonferroni posttests were
used for multiple comparisons. Two groups were compared with Student’s
t test for unpaired data. P values of 0.05 or less were considered significant.
Data Availability. All study data are included in the article and SI Appendix.
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